Regeneron Pharmaceuticals (REGN) is back in focus after the US FDA approved extended dosing intervals for EYLEA HD in wet age related macular degeneration and diabetic macular edema, easing treatment schedules for eligible patients.

At a share price of $763.04, Regeneron has a 1 year total shareholder return of 33.94%, while its year to date share price return is slightly negative. This suggests that longer term momentum has been strong even as recent trading has been more muted around the EYLEA HD decision and other pipeline updates.

If this kind of healthcare breakthrough has your attention, it could be a useful moment to see what else is moving in vision and treatment technology by checking out 37 healthcare AI stocks

With REGN trading at $763.04, sitting on a 34% 1 year total return and screens showing both an intrinsic discount and a gap to analyst targets, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 12.7% Undervalued

The most followed valuation narrative currently pegs Regeneron’s fair value at $873.78 versus the last close at $763.04, framing the stock as modestly undervalued and linking that gap to how EYLEA, Dupixent and the broader pipeline perform over time.

Regeneron's broad and advancing pipeline, including recent or upcoming pivotal data in immunology, oncology (notably Lynozyfic and odronextamab), genetic medicines, and obesity, positions the company to benefit from demographic driven increases in demand for advanced therapies and from the rise in personalized and precision medicine, supporting future revenue growth and pipeline driven earnings upside.

Curious what kind of revenue path, profit margins and valuation multiple need to align for that fair value to make sense? The core narrative relies on mid teens earnings growth assumptions, an improved margin profile over time, and a premium P/E relative to the wider biotech group. The exact mix of those inputs is where the story becomes more detailed.

Result: Fair Value of $873.78 (UNDERVALUED)

However, this hinges on EYLEA facing ongoing competition and pricing pressure, as well as on heavy R&D and manufacturing spend ultimately translating into commercially successful drugs rather than margin strain.

Another Angle On Valuation

The narrative fair value of $873.78 suggests modest undervaluation, but the current 17.4x P/E tells a different story. It is higher than the US Biotechs average of 16.2x, yet below both the peer average of 23x and a fair ratio of 25.3x. That mix points to both valuation risk and potential upside. The question is which signal investors choose to put more weight on.

Next Steps

With sentiment leaning cautiously optimistic so far, it makes sense to act while the details are fresh and test the thesis against your own expectations by checking the 2 key rewards.

Looking for more investment ideas?

If Regeneron has sharpened your interest, this is the moment to broaden your watchlist and spot other opportunities before they move out of reach.

• Target long term compounding potential by scanning for quality names trading below their estimated worth through the 62 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with higher yields and resilient payouts using the 13 dividend fortresses.
• Prioritise resilience by focusing on companies with robust finances through the solid balance sheet and fundamentals stocks screener (40 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.